The Series C round of funding will be used to establish Regentis’s European presence and expand its ongoing clinical effort of GelrinC, the biodegradable implant that enhances articular cartilage growth in damaged knee joints. It’s currently an investigational device and not available for sale in the United States, Europe or Israel.
GelrinC fits tightly within surrounding cartilage and underlying bone to closely restore cartilage to the pre-injury condition. Regentis is currently conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of the device.
More Articles on Orthopedic Devices:
Internal Fixation Systems Enters Into Agreement With Intelligent Orthopaedics for Trauma Device
U.S. Orthopedic Biomaterials Market Poised for Growth
TranS1 Q1 Revenue Plummets 26%
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.